Communiqués Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Recherche biotechnologique et médicale

Marché Fermé - Swiss Exchange Autres places de cotation 17:31:45 25/04/2025			Varia. 5j.	Varia. 1 janv.
43,10 ^CHF	0,00 %		+4,36 %	+4,23 %

24/04	Basilea reçoit un deuxième paiement d'étape pour les ventes de son médicament antifongique au Japon	MT
24/04	Basilea obtient un paiement d'étape d'Asahi Kasei Pharma	AW

Communiqués

Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea	24/04	GL
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea	24/04	AQ
Basilea shareholders approve all proposals of the board of directors at the annual general meeting	16/04	GL
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025	16/04	GL
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025	16/04	AQ
Basilea Pharmaceutica : AGM Invitation EN (Basilea AGM2025 Invitation EN)	16/04	PU
Basilea Pharmaceutica : Shareholder letter EN (Basilea AGM2025 Shareholder letter EN)	16/04	PU
Basilea Pharmaceutica : Updated March 25, 2025	26/03	PU
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	14/03	GL
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	14/03	AQ
Basilea Pharmaceutica : Updated February 18, 2025	18/02	PU
Basilea Pharmaceutica : Full-Year Report 2024 English	18/02	PU
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow	18/02	GL
Strong launch for Cresemba in Japan triggers first sales milestone payment from AKP to Basilea	05/02	GL
Strong sales growth for Cresemba and Zevtera trigger further milestone payments to Basilea	28/01	GL
Basilea provides portfolio update and outlook	08/01	GL
Basilea provides portfolio update and outlook	08/01	AQ
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics	23/12	GL
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics	23/12	AQ
Basilea Pharmaceutica : Updated December 16, 2024	16/12	PU
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States	16/12	GL
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States	16/12	AQ
Basilea Pharmaceutica : Updated October 22, 2024	22/10/24	PU
Basilea Pharmaceutica : Updated October 10, 2024	10/10/24	PU
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year	10/10/24	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Basilea Pharmaceutica AG

Actions

BSLN

CH0011432447

Recherche biotechnologique et médicale

Communiqués

Filtres